HX15001

HX15001 is an investigational drug under development by Helixon Biotechnology. It is currently being evaluated in a phase 1, randomized, double-blind, placebo-controlled, single dose escalation study in healthy adult volunteers. The primary objective is to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of HX15001. The specific mechanism of action, modality, molecular target, and primary indication have not been publicly disclosed as of the latest available information. No evidence indicates approval for any disease or use in patient populations beyond clinical trial settings[1][3][5][9][10].

Other names

HX15001HX-15001HX 15001